Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Successfully eliminating the so-called pill penalty faces an uphill battle, whether it’s attempted through executive changes ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 a share, up ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

Jardiance is a medication doctors prescribe to treat heart failure and type 2 diabetes. Most Medicare Part D prescription drug plans include coverage for Jardiance. Part C plans with drug coverage ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low ...

She has had several such episodes this year, and they seem to be coming more frequently. “She stares and gets a gray color and then she gets confused,” her daughter, Susan Larson, 61, said ...